MA56783B1 - Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci - Google Patents

Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci

Info

Publication number
MA56783B1
MA56783B1 MA56783A MA56783A MA56783B1 MA 56783 B1 MA56783 B1 MA 56783B1 MA 56783 A MA56783 A MA 56783A MA 56783 A MA56783 A MA 56783A MA 56783 B1 MA56783 B1 MA 56783B1
Authority
MA
Morocco
Prior art keywords
ivosidenib
preparing
synthesis
preparation
relates
Prior art date
Application number
MA56783A
Other languages
English (en)
Inventor
Jacob Sizemore
Shijie Zhang
Nha Vo
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA56783B1 publication Critical patent/MA56783B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne un procédé de préparation d'un solvate éthanol cristallin sensiblement pur et diastéréomériquement pur du composé iia et son utilisation pour la synthétisation de l'ivosidenib.
MA56783A 2019-08-08 2020-08-07 Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci MA56783B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962884480P 2019-08-08 2019-08-08
PCT/US2020/045368 WO2021026436A1 (fr) 2019-08-08 2020-08-07 Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci

Publications (1)

Publication Number Publication Date
MA56783B1 true MA56783B1 (fr) 2023-10-31

Family

ID=74504162

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56783A MA56783B1 (fr) 2019-08-08 2020-08-07 Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci

Country Status (29)

Country Link
US (1) US20230025411A1 (fr)
EP (1) EP4010331B1 (fr)
JP (1) JP2022544143A (fr)
KR (1) KR20220061971A (fr)
CN (1) CN114555584A (fr)
AU (1) AU2020327013A1 (fr)
BR (1) BR112022002253A2 (fr)
CA (1) CA3150028A1 (fr)
CL (1) CL2022000310A1 (fr)
CO (1) CO2022001991A2 (fr)
CR (1) CR20220090A (fr)
DK (1) DK4010331T3 (fr)
EC (1) ECSP22016924A (fr)
ES (1) ES2967909T3 (fr)
FI (1) FI4010331T3 (fr)
HR (1) HRP20231618T1 (fr)
HU (1) HUE064193T2 (fr)
IL (1) IL290377A (fr)
LT (1) LT4010331T (fr)
MA (1) MA56783B1 (fr)
MD (1) MD4010331T2 (fr)
MX (1) MX2022001619A (fr)
PE (1) PE20221761A1 (fr)
PL (1) PL4010331T3 (fr)
PT (1) PT4010331T (fr)
RS (1) RS64934B1 (fr)
SI (1) SI4010331T1 (fr)
TW (1) TW202120491A (fr)
WO (1) WO2021026436A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067445A2 (fr) 2004-12-22 2006-06-29 Astrazeneca Ab Composes chimiques
ATE541844T1 (de) 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
WO2019104318A1 (fr) * 2017-11-27 2019-05-31 Teva Pharmaceuticals Usa, Inc. Formes à l'état solide d'ivosidénib
CA3103498A1 (fr) * 2018-07-06 2020-01-09 Agios Pharmaceuticals, Inc. Formes d'ivosidenib et compositions pharmaceutiques
WO2020127887A1 (fr) * 2018-12-21 2020-06-25 Sandoz Ag Procédé de préparation d'un produit intermédiaire d'ivosidénib

Also Published As

Publication number Publication date
RS64934B1 (sr) 2023-12-29
WO2021026436A1 (fr) 2021-02-11
CA3150028A1 (fr) 2021-02-11
CL2022000310A1 (es) 2022-11-25
TW202120491A (zh) 2021-06-01
PL4010331T3 (pl) 2024-03-11
MD4010331T2 (ro) 2024-03-31
AU2020327013A1 (en) 2022-03-24
EP4010331B1 (fr) 2023-10-04
BR112022002253A2 (pt) 2022-07-05
IL290377A (en) 2022-04-01
LT4010331T (lt) 2023-11-10
ECSP22016924A (es) 2022-06-30
SI4010331T1 (sl) 2024-02-29
ES2967909T3 (es) 2024-05-06
CR20220090A (es) 2022-08-24
JP2022544143A (ja) 2022-10-17
EP4010331A1 (fr) 2022-06-15
KR20220061971A (ko) 2022-05-13
PE20221761A1 (es) 2022-11-11
CO2022001991A2 (es) 2022-07-29
PT4010331T (pt) 2024-01-08
DK4010331T3 (da) 2023-12-18
HUE064193T2 (hu) 2024-02-28
HRP20231618T1 (hr) 2024-03-15
FI4010331T3 (fi) 2023-12-28
US20230025411A1 (en) 2023-01-26
MX2022001619A (es) 2022-07-19
CN114555584A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
MX2021012756A (es) Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este.
AR043940A1 (es) Inhibidores de sulfonamidas heterociclicas que contienen fluor- y trifluoralquilo de la produccion de beta amiloides y derivados de los mismos
MX2021005584A (es) Proceso para la preparación de (s)-nicotina de miosmina.
UA101352C2 (uk) Конденсоване похідне амінодигідротіазину
NO20054669L (no) Substituerte kinobenzoxazinanaloger
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
MA40895B1 (fr) Synthèse de copanlisib et son sel de dichlorhydrate
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MX2022005403A (es) Forma cristalina de base libre de un receptor del componente c5a de complemento.
MX2020002436A (es) Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos.
MX2020009843A (es) Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto.
MA56783B1 (fr) Procédé de préparation d'ivosidenib et d'un intermédiaire de celui-ci
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
MX2021007258A (es) Composiciones de esparsentan amorfas.
FR3101348B1 (fr) PROCÉDÉ DE PRÉPARATION DE (15α,16α,17β)-OESTRA-1,3,5(10)-TRIÈNE-3,15,16,17-TÉTROL (OESTÉTROL) ET INTERMÉDIAIRES DUDIT PROCÉDÉ
MX2021006702A (es) Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen.
MX2021000942A (es) Derivado de lactama condensado.
CO2022007808A2 (es) Polimorfos del compuesto antifúngico de triazol pc945
PH12021550248A1 (en) Borate of azetidine derivative
EP4249491A3 (fr) Procédé pour la préparation d'énol éther bicyclique
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
AR115012A1 (es) Derivados de aminopropoxifenilo y bencil 1-oxa-4,9-diazaespiroundecano con actividad multimodal contra el dolor